UA112810U - Спосіб корекції нейтропенії як наслідку етіотропної терапії хронічного гепатиту с - Google Patents
Спосіб корекції нейтропенії як наслідку етіотропної терапії хронічного гепатиту с Download PDFInfo
- Publication number
- UA112810U UA112810U UAU201607685U UAU201607685U UA112810U UA 112810 U UA112810 U UA 112810U UA U201607685 U UAU201607685 U UA U201607685U UA U201607685 U UAU201607685 U UA U201607685U UA 112810 U UA112810 U UA 112810U
- Authority
- UA
- Ukraine
- Prior art keywords
- therapy
- neutropenia
- chronic hepatitis
- peripheral blood
- methyluracil
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 24
- 208000006154 Chronic hepatitis C Diseases 0.000 title claims abstract description 21
- 208000005176 Hepatitis C Diseases 0.000 title claims abstract description 21
- 208000010710 hepatitis C virus infection Diseases 0.000 title claims abstract description 21
- 208000004235 neutropenia Diseases 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims abstract description 13
- 238000012937 correction Methods 0.000 title description 6
- XBCXJKGHPABGSD-UHFFFAOYSA-N methyluracil Natural products CN1C=CC(=O)NC1=O XBCXJKGHPABGSD-UHFFFAOYSA-N 0.000 claims abstract description 19
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims abstract description 19
- 235000012054 meals Nutrition 0.000 claims abstract description 6
- 238000012544 monitoring process Methods 0.000 claims abstract description 4
- 230000003442 weekly effect Effects 0.000 claims abstract description 4
- 210000000440 neutrophil Anatomy 0.000 claims abstract description 3
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 abstract description 22
- 239000011886 peripheral blood Substances 0.000 abstract description 22
- 239000003814 drug Substances 0.000 description 17
- 229940079593 drug Drugs 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 102000014150 Interferons Human genes 0.000 description 10
- 108010050904 Interferons Proteins 0.000 description 10
- 229940079322 interferon Drugs 0.000 description 7
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 229960000329 ribavirin Drugs 0.000 description 5
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 3
- 229940047124 interferons Drugs 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108010083475 myelopeptides Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000881711 Acipenser sturio Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000002169 Metam Substances 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 230000003160 anti-catabolic effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- HYVVJDQGXFXBRZ-UHFFFAOYSA-N metam Chemical compound CNC(S)=S HYVVJDQGXFXBRZ-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201607685U UA112810U (xx) | 2016-07-12 | 2016-07-12 | Спосіб корекції нейтропенії як наслідку етіотропної терапії хронічного гепатиту с |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201607685U UA112810U (xx) | 2016-07-12 | 2016-07-12 | Спосіб корекції нейтропенії як наслідку етіотропної терапії хронічного гепатиту с |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA112810U true UA112810U (xx) | 2016-12-26 |
Family
ID=58044964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAU201607685U UA112810U (xx) | 2016-07-12 | 2016-07-12 | Спосіб корекції нейтропенії як наслідку етіотропної терапії хронічного гепатиту с |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA112810U (xx) |
-
2016
- 2016-07-12 UA UAU201607685U patent/UA112810U/uk unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004073706A1 (ja) | リバビリン／インターフェロン併用療法の副作用軽減剤 | |
| WO2004043389B1 (en) | Methods of treating cancer and related methods | |
| JP2012144512A (ja) | 脳腫瘍を治療するための医薬組成物又は脳腫瘍細胞のテモゾロミド耐性を低減させるための医薬組成物、及びその使用 | |
| JPH05505615A (ja) | 医薬組成物 | |
| JP4234439B2 (ja) | Ｉｌ−１２発現調節剤 | |
| CN1111414C (zh) | 镁盐或镁配合物的制药用途 | |
| CN100349609C (zh) | 肝硬化治疗药 | |
| RU2306934C1 (ru) | Способ лечения больных хроническим вирусным гепатитом c | |
| EP0502313A2 (en) | Method for insuring adequate intracellular glutathione in tissue | |
| RU2293572C1 (ru) | Способ лечения хронического вирусного гепатита с генотип-2 с умеренной активностью | |
| UA112810U (xx) | Спосіб корекції нейтропенії як наслідку етіотропної терапії хронічного гепатиту с | |
| JPH03135918A (ja) | 免疫賦活剤 | |
| WO2002015664A2 (en) | Methods of preventing or treating west nile virus and other infections | |
| EA022952B1 (ru) | Способ лечения вирусных гепатитов b и c | |
| JPH06340549A (ja) | ネコの呼吸器疾患治療剤とその治療剤を用いる治療方法 | |
| CN100464753C (zh) | 膦甲酸钠组合物 | |
| Worman et al. | Hypersensitivity reaction associated with acute hepatic dysfunction following a single intravenous dose of procainamide | |
| Brodsky et al. | Effect of testosterone enanthate and alkylating agents on multiple myeloma | |
| EP1888085A1 (en) | Methods for providing palliative care with avr118 | |
| RU2256460C2 (ru) | Способ лечения неспецифической бронхопневмонии у телят | |
| RU2196576C1 (ru) | Способ лечения больных геморрагической лихорадкой с почечным синдромом (глпс) | |
| RU2094438C1 (ru) | Инъекционное средство для гемокоррекции | |
| Ramatillah et al. | DRUG RELATED PROBLEMS THAT OCCURRED IN PATIENT SEPSIS MACROVASCULAR DISEASE COMPLICATIONS GENERAL HOSPITAL TREATMENT ROOM CENTRAL OF THE ARMY (ARMY HOSPITAL) GATOT SUBROTO. | |
| CN107617101A (zh) | 含唑来膦酸和白细胞介素2的药物组合及其应用 | |
| RU2599037C1 (ru) | Способ лечения острого гепатита в или с тяжелого течения |